Zoetis Inc.

ZTS

US98978V1035

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:46:10 2026-01-12 am EST			5-day change	1st Jan Change
126.64 ^USD	-0.42%		-2.19%	+0.57%

Dec. 17	Morgan Stanley Adjusts Zoetis Price Target to $160 From $175, Maintains Overweight Rating	MT
Dec. 16	Sector Update: Health Care Stocks Edge Higher Premarket Tuesday	MT

Zoetis CEO Says Its Arthritis Drug for Dogs Is Safe

Published on 01/14/2025 at 03:20 pm EST - Modified on 01/14/2025 at 03:31 pm EST

MT Newswires

Zoetis Inc.

-0.42%

Zoetis (ZTS) CEO Kristen Peck talks about expanding their line of medications and she says the market for animal care products is growing. Peck also says its arthritis drug for dogs, Librela, is safe to use. She speaks at the JPMorgan Healthcare Conference.

Bloomberg videos, provided by MT Newswires

Latest news about Zoetis Inc.

Dec. 17	Morgan Stanley Adjusts Zoetis Price Target to $160 From $175, Maintains Overweight Rating	MT
Dec. 16	Sector Update: Health Care Stocks Edge Higher Premarket Tuesday	MT
Dec. 16	The Fed's Favorite Numbers?
Dec. 16	Zoetis Prices $1.75 Billion Convertible Notes Offering	MT
Dec. 16	Zoetis says co priced offering of $1.75 billion aggregate principal amount of 0.25% convertible senior notes due 2029	RE
Dec. 15	Zoetis to Offer $1.75 Billion Convertible Notes Offering	MT
Dec. 15	Zoetis announces proposed $1.75 billion convertible senior notes offering	RE
Dec. 15	BofA Securities Downgrades Zoetis to Neutral From Buy	MT
Dec. 15	Zoetis shares fall 2.6% premarket after co announces proposed $1.75 billion convertible senior notes offering	RE
Dec. 11	Zoetis Ups Quarterly Dividend to $0.53 per Share, Payable Mar. 3 to Holders of Record on Jan. 20	MT
Dec. 11	Zoetis declares first quarter 2026 dividend; board approves 6% payment increase	RE
Dec. 11	Zoetis Inc. Declares Dividend for the First Quarter of 2026, Payable on March 3, 2026	CI
Dec. 10	HSBC Adjusts Zoetis Price Target to $140 From $180, Maintains Buy Rating	MT
Dec. 09	Barclays Initiates Zoetis at Equalweight With $136 Price Target	MT
Dec. 05	Zoetis Says Health Canada Approves Long-Lasting Cat Osteoarthritis Drug	MT
Dec. 05	Zoetis Inc. Receives Health Canada Approval for Portela?? (Relfovetmab Injection) to Alleviate Pain Associated with Osteoarthritis in Cats	CI
Dec. 05	Zoetis receives Health Canada approval for Portela (Relfovetmab injection)	RE
Dec. 04	Zoetis Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-04-2025 09:30 AM
Dec. 03	TD Cowen Adjusts Zoetis Price Target to $150 From $189, Maintains Buy Rating	MT
Dec. 03	Rothschild & Co Redburn Adjusts Price Target on Zoetis to $165 From $195, Maintains Buy Rating	MT
Dec. 02	Zoetis Inc. - Special Call
Nov. 26	Zoetis receives European Commission marketing authorization for Lenivia (izenivetmab) to reduce pain associated with osteoarthritis (OA) in dogs	RE
Nov. 26	Zoetis Inc. Receives European Commission Marketing Authorization for Lenivia®? (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs	CI
Nov. 21	KeyBanc Initiates Zoetis at Sector Weight	MT
Nov. 18	Traders Strap In, Again

Chart Zoetis Inc.

Duration

Period

ZTS: Dynamic Chart

Company Profile

Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows: - companion animal (67.8%): cats and dogs (95.5% of net sales) and horses (4.5%); - livestock (31.3%): cattle (52.8% of sales), poultry (18.2%), swine (17.8%), fish (8.4%) and other (2.8%); - other (0.9%). Net sales break down by family of products into parasiticides (23.3%), vaccines (19.7%), dermatological products (17.9%), anti-infectives (11.9%), pain relievers (9.2%), diagnostic products (4.2%), medicated feed additives (3.2%) and other (10.6%). At the end of 2024, the group has 22 production sites worldwide. The United States accounts for 54.8% of net sales.

Employees

13,800

Sector

Pharmaceuticals

Calendar

01:30pm - J.P. Morgan Healthcare Conference

More about the company